Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Fischereder

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Frontiers in Medicine|June 27, 2022
Disqualification of Donor and Recipient Candidates From the Living Kidney Donation Program: Experience of a Single-Center in GermanyMelissa Grigorescu, Stephan Kemmner, Ulf Schönermarck, et al.
American Journal of Nephrology|March 29, 2002
Effects of aortic stenosis on renal renin, angiotensin receptor, endothelin and NOS gene expression in ratsMartin C Kammerl, Daniela Grimm, Eckhard P Kromer, et al.
Atherosclerosis|January 23, 2010
Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes?Bernd Krüger, Andreas Walberer, Jens Debler, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 11, 2012
Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantationMarkus Guba, Johann Pratschke, Christian Hugo, et al.
Kidney360|August 21, 2024
Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after HyperkalemiaMaria K Svensson, Michael Fischereder, Paul R Kalra, et al.
Clinical Kidney Journal|September 3, 2021
Sirolimus in renal transplant recipients with malignancies in GermanyMarcel G Naik, Wolfgang Arns, Klemens Budde, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 19, 2016
De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding abilityTeresa Kauke, Cornelia Oberhauser, Viviane Lin, et al.
Plos One|September 8, 2018
Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosisJohn J Bissler, Norio Nonomura, Klemens Budde, et al.
Plos One|August 7, 2020
Early conversion to a CNI-free immunosuppression with SRL after renal transplantation-Long-term follow-up of a multicenter trialJoachim Andrassy, Markus Guba, Antje Habicht, et al.
Clinical Transplantation|December 31, 2013
Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter databaseMarcel G Naik, Katharina M Heller, Wolfgang Arns, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Frontiers in Medicine|June 27, 2022
Disqualification of Donor and Recipient Candidates From the Living Kidney Donation Program: Experience of a Single-Center in GermanyMelissa Grigorescu, Stephan Kemmner, Ulf Schönermarck, et al.
American Journal of Nephrology|March 29, 2002
Effects of aortic stenosis on renal renin, angiotensin receptor, endothelin and NOS gene expression in ratsMartin C Kammerl, Daniela Grimm, Eckhard P Kromer, et al.
Atherosclerosis|January 23, 2010
Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes?Bernd Krüger, Andreas Walberer, Jens Debler, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 11, 2012
Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantationMarkus Guba, Johann Pratschke, Christian Hugo, et al.
Kidney360|August 21, 2024
Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after HyperkalemiaMaria K Svensson, Michael Fischereder, Paul R Kalra, et al.
Clinical Kidney Journal|September 3, 2021
Sirolimus in renal transplant recipients with malignancies in GermanyMarcel G Naik, Wolfgang Arns, Klemens Budde, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 19, 2016
De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding abilityTeresa Kauke, Cornelia Oberhauser, Viviane Lin, et al.
Plos One|September 8, 2018
Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosisJohn J Bissler, Norio Nonomura, Klemens Budde, et al.
Plos One|August 7, 2020
Early conversion to a CNI-free immunosuppression with SRL after renal transplantation-Long-term follow-up of a multicenter trialJoachim Andrassy, Markus Guba, Antje Habicht, et al.
Clinical Transplantation|December 31, 2013
Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter databaseMarcel G Naik, Katharina M Heller, Wolfgang Arns, et al.
Pageof 12